Study Highlights Ethnic Diversity of Lupus-Linked Genes
By LabMedica International staff writers Posted on 03 Aug 2017 |
A large genotyping study has identified multiple regions of the genome linked to the autoimmune disease systemic lupus erythematosus (SLE) in individuals of European, African, and Hispanic Amerindian ancestry.
SLE is an autoimmune disease with marked gender and ethnic disparities. For example SLE strikes women nine times more frequently than men and its onset is most common during the childbearing years. Furthermore, African-American and Hispanic women are two to three times more likely to develop lupus and tend to have more severe cases than Caucasian women.
A recent study conducted by investigators at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) and colleagues in Oklahoma, the United Kingdom, and at the biotechnology company Genentech Inc. (San Francisco, CA, USA) analyzed genetic data from 27,574 individuals of European, African American, and Hispanic ancestry using Immunochip genotyping technology that had been designed specifically for autoimmune diseases.
The investigators reported that they had identified 58 regions of the genome linked to SLE in Caucasians, nine in African Americans, and 16 in Hispanics. These regions appeared to be independent of association with HLA (Human Leukocyte Antigen), and nearly 50% of these regions had multiple genetic variants that predisposed to SLE.
"This study is the largest multi-ethnic lupus genetics study to date and allowed us to identify many new genetic markers, some of which are specific to individual ethnic groups and others that are shared across ethnicities," said first author Dr. Carl Langefeld, professor of biostatistical sciences at Wake Forest Baptist Medical Center. "With this information, we can begin to better understand the differences in the rates and severity of disease across ethnic groups. In addition, we observed that many of the genetic markers associated with lupus are shared across numerous autoimmune diseases, and those that are not shared may allow us to understand why a person develops lupus instead of another autoimmune disease. These results will help us identify the biological pathways that pharmaceutical companies may target, and ultimately, develop personalized medicine for the treatment of lupus."
The study was published in the July 17, 2017, online edition of the journal Nature Communications.
Related Links:
Wake Forest Baptist Medical Center
Genentech
SLE is an autoimmune disease with marked gender and ethnic disparities. For example SLE strikes women nine times more frequently than men and its onset is most common during the childbearing years. Furthermore, African-American and Hispanic women are two to three times more likely to develop lupus and tend to have more severe cases than Caucasian women.
A recent study conducted by investigators at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) and colleagues in Oklahoma, the United Kingdom, and at the biotechnology company Genentech Inc. (San Francisco, CA, USA) analyzed genetic data from 27,574 individuals of European, African American, and Hispanic ancestry using Immunochip genotyping technology that had been designed specifically for autoimmune diseases.
The investigators reported that they had identified 58 regions of the genome linked to SLE in Caucasians, nine in African Americans, and 16 in Hispanics. These regions appeared to be independent of association with HLA (Human Leukocyte Antigen), and nearly 50% of these regions had multiple genetic variants that predisposed to SLE.
"This study is the largest multi-ethnic lupus genetics study to date and allowed us to identify many new genetic markers, some of which are specific to individual ethnic groups and others that are shared across ethnicities," said first author Dr. Carl Langefeld, professor of biostatistical sciences at Wake Forest Baptist Medical Center. "With this information, we can begin to better understand the differences in the rates and severity of disease across ethnic groups. In addition, we observed that many of the genetic markers associated with lupus are shared across numerous autoimmune diseases, and those that are not shared may allow us to understand why a person develops lupus instead of another autoimmune disease. These results will help us identify the biological pathways that pharmaceutical companies may target, and ultimately, develop personalized medicine for the treatment of lupus."
The study was published in the July 17, 2017, online edition of the journal Nature Communications.
Related Links:
Wake Forest Baptist Medical Center
Genentech
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans